TY - JOUR
T1 - Corrigendum to “A case-control study to identify molecular risk factors for local recurrence in young breast cancer patients” [Radiother Oncol 156 (2021) 127-135] (Radiotherapy and Oncology (2021) 156(127-135) (S0167814020311956), (10.1016/j.radonc.2020.11.025))
AU - Bosma, Sophie C. J.
AU - Hoogstraat, Marlous
AU - van Werkhoven, Erik
AU - de Maaker, Michiel
AU - van der Leij, Femke
AU - Elkhuizen, Paula H. M.
AU - Fourquet, Alain
AU - Poortmans, Philip
AU - Boersma, Liesbeth J.
AU - Bartelink, Harry
AU - Young Boost Trial research group
AU - van de Vijver, Marc J.
N1 - Publisher Copyright: © 2021
PY - 2021/10
Y1 - 2021/10
N2 - The authors regret that in the above-mentioned article the acknowledgements section was not complete. Important contributors were missing from the list. The acknowledgements in full are below, and have been amended online. Furthermore, the affiliation of Femke van der Leij changed from the Netherlands Cancer Institute to UMC Utrecht. Also, we acknowledge and thank Alain Fourquet, project leader in France, for coordinating the Young Boost Trial in France and the following investigators for their active participation: L. Scheijmans, Tilburg (NL), A.H. Westenberg, Arnhem (NL), D. Schinagl, Nijmegen (NL), M. van Hezewijk, Leiden (NL); M.J.C. van der Sangen Eindhoven (NL); M.C. Stenfert Kroese, Deventer (NL); J.J.Jobsen, Enschede (NL); J.M. Immink, Delft (NL); M.E. Mast, Den Haag (NL); F.M. Gescher, Den Haag (NL); N. Bijker, Amsterdam (NL); J.W.M. Mens, Rotterdam (NL); W.G.J.M. Smit, Leeuwarden (NL); D.H.F. Rietveld, éAmsterdam (NL); J.H. Maduro, UMCG, Groningen (NL); C. Lemansky, Montpellier (Fr), I. Lecouillard, Rennes (Fr); C Breton-Callu, Bordeaux (Fr); H. Marsiglia, Villejuif (Fr); J. Thariat, Nice (Fr); A. Benyoucef, Rouen (Fr); A. Labib, Saint Cloud (Fr); M. Aumont, Saint Herblain (Fr); P. Bontemps, Besancon (Fr); C. Le Foll, Lagny (Fr); Y. Belkacemi, Créteil (Fr); O. Chapet, Lyon (Fr); V. Strnad, Erlangen (De).
AB - The authors regret that in the above-mentioned article the acknowledgements section was not complete. Important contributors were missing from the list. The acknowledgements in full are below, and have been amended online. Furthermore, the affiliation of Femke van der Leij changed from the Netherlands Cancer Institute to UMC Utrecht. Also, we acknowledge and thank Alain Fourquet, project leader in France, for coordinating the Young Boost Trial in France and the following investigators for their active participation: L. Scheijmans, Tilburg (NL), A.H. Westenberg, Arnhem (NL), D. Schinagl, Nijmegen (NL), M. van Hezewijk, Leiden (NL); M.J.C. van der Sangen Eindhoven (NL); M.C. Stenfert Kroese, Deventer (NL); J.J.Jobsen, Enschede (NL); J.M. Immink, Delft (NL); M.E. Mast, Den Haag (NL); F.M. Gescher, Den Haag (NL); N. Bijker, Amsterdam (NL); J.W.M. Mens, Rotterdam (NL); W.G.J.M. Smit, Leeuwarden (NL); D.H.F. Rietveld, éAmsterdam (NL); J.H. Maduro, UMCG, Groningen (NL); C. Lemansky, Montpellier (Fr), I. Lecouillard, Rennes (Fr); C Breton-Callu, Bordeaux (Fr); H. Marsiglia, Villejuif (Fr); J. Thariat, Nice (Fr); A. Benyoucef, Rouen (Fr); A. Labib, Saint Cloud (Fr); M. Aumont, Saint Herblain (Fr); P. Bontemps, Besancon (Fr); C. Le Foll, Lagny (Fr); Y. Belkacemi, Créteil (Fr); O. Chapet, Lyon (Fr); V. Strnad, Erlangen (De).
UR - http://www.scopus.com/inward/record.url?scp=85107759438&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.radonc.2021.03.037
DO - https://doi.org/10.1016/j.radonc.2021.03.037
M3 - Comment/Letter to the editor
C2 - 34120786
SN - 0167-8140
VL - 163
SP - 244
JO - Radiotherapy and oncology
JF - Radiotherapy and oncology
ER -